Transversal sero-epidemiological study of Bordetella pertussis in Tehran, Iran.
Adolescent
Age Factors
Antibodies, Bacterial
/ blood
Bordetella pertussis
/ immunology
Child
Child, Preschool
Female
Humans
Immunization Schedule
Immunization, Secondary
Immunoglobulin G
/ blood
Iran
/ epidemiology
Male
Pertussis Vaccine
/ administration & dosage
Seroepidemiologic Studies
Whooping Cough
/ epidemiology
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
03
2020
accepted:
15
08
2020
entrez:
2
9
2020
pubmed:
2
9
2020
medline:
27
10
2020
Statut:
epublish
Résumé
Pertussis remains endemic despite high vaccine coverage in infants and toddlers. Pertussis vaccines confer protection but immunity wanes overtime and boosters are needed in a lifetime. Iran, eligible for the Expanded Program on Immunization that includes the primary immunization, implemented two additional booster doses using a whole-cell vaccine (wPV) at 18 months-old and about 6 years-old. Duration of protection induced by the wPVs currently in use and their impact as pre-school booster are not well documented. This study aimed at assessing vaccination compliance and at estimating the duration of protection conferred by vaccination with wPV in children aged < 15 years in Tehran, Iran. Detailed information on vaccination history and capillary blood samples were obtained from 1047 children aged 3-15 years who completed the 3 doses-primary pertussis immunization, in Tehran. Anti-pertussis toxin IgG levels were quantified by ELISA. Compliance was very high with 93.3% of children who received the three primary and 1st booster doses in a timely manner. Timeliness of the 2nd booster was lower (63.3%). Rate of seropositive samples continuously and significantly increased from 1-2 to 5-6 years after 1st booster attaining 30.4% of children exhibiting serological sign of recent contact with B. pertussis. Second booster dating back 1 or 2 years was associated with high antibody titers, which significantly decreased within 3 years from injection. Among children who received 2nd booster injection more than 2 years before serum analysis, seroprevalence of pertussis infection was 8.4% and seropositivity rate was higher from the 10 years-old group. Seropositivity in children aged 6-7 years with no 2nd booster supports the need for a vaccination at that age. Adolescent booster may also be considered.
Identifiants
pubmed: 32870922
doi: 10.1371/journal.pone.0238398
pii: PONE-D-20-08084
pmc: PMC7462262
doi:
Substances chimiques
Antibodies, Bacterial
0
Immunoglobulin G
0
Pertussis Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0238398Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Pathog Dis. 2015 Oct;73(7):
pubmed: 26208655
East Mediterr Health J. 2014 Oct 20;20(10):623-6
pubmed: 25356693
J Pediatr. 1998 Jun;132(6):983-8
pubmed: 9627590
Vaccine. 2013 Aug 12;31(36):3732-8
pubmed: 23742995
Wkly Epidemiol Rec. 2015 Aug 28;90(35):433-58
pubmed: 26320265
Roum Arch Microbiol Immunol. 2013 Oct-Dec;72(4):250-4
pubmed: 24923108
Lancet Infect Dis. 2011 Jul;11(7):557-70
pubmed: 21600850
Iran J Public Health. 2012;41(10):65-71
pubmed: 23304664
Vaccine. 2016 May 23;34(24):2635-43
pubmed: 27109562
Lancet Infect Dis. 2017 Sep;17(9):974-980
pubmed: 28623146
Clin Diagn Lab Immunol. 1996 Jan;3(1):93-7
pubmed: 8770511
Vaccine. 2018 Dec 18;36(52):7936-7942
pubmed: 30448334
J Clin Microbiol. 2010 Dec;48(12):4459-63
pubmed: 20943873
Jundishapur J Microbiol. 2014 Nov;7(11):e12421
pubmed: 25774274
Emerg Infect Dis. 2008 Jul;14(7):1159-61
pubmed: 18598649
Eur J Clin Microbiol Infect Dis. 2011 Mar;30(3):307-12
pubmed: 21069406
Hum Vaccin Immunother. 2013 Jan;9(1):112-4
pubmed: 23442584
Lancet Infect Dis. 2017 Sep;17(9):889-890
pubmed: 28623145
J Med Microbiol. 2018 Oct;67(10):1426-1456
pubmed: 30222536
Vaccine. 2017 Oct 27;35(45):6083-6088
pubmed: 28974408
Pediatr Infect Dis J. 2015 Apr;34(4):333-8
pubmed: 25764094
N Engl J Med. 1996 Feb 8;334(6):349-55
pubmed: 8538705
J Infect Dis. 2014 Apr 1;209 Suppl 1:S10-5
pubmed: 24158958
Vaccine. 2003 May 16;21(17-18):2003-14
pubmed: 12706690
BMC Med. 2015 Jun 24;13:146
pubmed: 26103968
Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1893-1900
pubmed: 30094521
J Res Health Sci. 2015 Winter;15(1):54-8
pubmed: 25821027
J Clin Microbiol. 2000 Feb;38(2):800-6
pubmed: 10655388
PLoS One. 2018 Nov 28;13(11):e0207209
pubmed: 30485291
Epidemiol Infect. 2005 Feb;133(1):159-71
pubmed: 15724723
Vaccine. 1998 Dec;16(20):1907-16
pubmed: 9796042
Adv Exp Med Biol. 2019;1183:137-149
pubmed: 31342458
Eur J Clin Microbiol Infect Dis. 1999 May;18(5):341-5
pubmed: 10421041
Iran J Pediatr. 2016 Jun 12;26(4):e5514
pubmed: 27729960